Changes

Jump to navigation Jump to search
no edit summary
Line 4: Line 4:  
{{Under Construction}}
 
{{Under Construction}}
   −
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-03. The original page can be found at [[HAEM4:Chronic Neutrophilic Leukemia (CNL)]].
+
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-30. The original page can be found at [[HAEM4:Chronic Neutrophilic Leukemia (CNL)]].
 
}}</blockquote>
 
}}</blockquote>
 
==Primary Author(s)*==
 
==Primary Author(s)*==
Line 16: Line 16:  
__TOC__
 
__TOC__
   −
==Cancer Category/Type==
+
==Cancer Category / Type==
    
[[Myeloproliferative Neoplasms (MPN)|Myeloproliferative Neoplasms]]
 
[[Myeloproliferative Neoplasms (MPN)|Myeloproliferative Neoplasms]]
Line 149: Line 149:  
The presenting features may be non-specific with organomegaly involving the liver, spleen or both, mucocutaneous bleeding, and bruising.<ref name=":0" />  The disease has a variable prognosis with some cases rapidly evolving<ref name=":6" /><ref>{{Cite journal|last=Zittoun|first=R.|last2=Réa|first2=D.|last3=Ngoc|first3=L. H.|last4=Ramond|first4=S.|date=1994-02|title=Chronic neutrophilic leukemia. A study of four cases|url=https://pubmed.ncbi.nlm.nih.gov/8148416|journal=Annals of Hematology|volume=68|issue=2|pages=55–60|doi=10.1007/BF01715131|issn=0939-5555|pmid=8148416}}</ref>; others may have an indolent course spanning decades.<ref>{{Cite journal|last=Uppal|first=Guldeep|last2=Gong|first2=Jerald|date=2015-09|title=Chronic neutrophilic leukaemia|url=https://pubmed.ncbi.nlm.nih.gov/26082513|journal=Journal of Clinical Pathology|volume=68|issue=9|pages=680–684|doi=10.1136/jclinpath-2015-203060|issn=1472-4146|pmid=26082513}}</ref>  Survival is variable, overall mean survival being between 21-30 months.
 
The presenting features may be non-specific with organomegaly involving the liver, spleen or both, mucocutaneous bleeding, and bruising.<ref name=":0" />  The disease has a variable prognosis with some cases rapidly evolving<ref name=":6" /><ref>{{Cite journal|last=Zittoun|first=R.|last2=Réa|first2=D.|last3=Ngoc|first3=L. H.|last4=Ramond|first4=S.|date=1994-02|title=Chronic neutrophilic leukemia. A study of four cases|url=https://pubmed.ncbi.nlm.nih.gov/8148416|journal=Annals of Hematology|volume=68|issue=2|pages=55–60|doi=10.1007/BF01715131|issn=0939-5555|pmid=8148416}}</ref>; others may have an indolent course spanning decades.<ref>{{Cite journal|last=Uppal|first=Guldeep|last2=Gong|first2=Jerald|date=2015-09|title=Chronic neutrophilic leukaemia|url=https://pubmed.ncbi.nlm.nih.gov/26082513|journal=Journal of Clinical Pathology|volume=68|issue=9|pages=680–684|doi=10.1136/jclinpath-2015-203060|issn=1472-4146|pmid=26082513}}</ref>  Survival is variable, overall mean survival being between 21-30 months.
 
</blockquote>
 
</blockquote>
==Individual Region Genomic Gain/Loss/LOH==
+
==Individual Region Genomic Gain / Loss / LOH==
    
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>
 
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>
Line 229: Line 229:     
</blockquote>
 
</blockquote>
==Gene Mutations (SNV/INDEL)==
+
==Gene Mutations (SNV / INDEL)==
    
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>
 
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>

Navigation menu